Azithromycin-induced hearing loss

Lo, Shiaw-Huei Eunice; Kotabe, Sharon; Mitsunaga, Lisa

doi:10.1093/ajhp/56.4.380

Cited by 18 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He developed decreased hearing, bilateral tinnitus, and dizziness. An audiogram showed moderate to severe SNHL that improved over 3 weeks after stopping azithromycin (44). Among a group of 21 HIV+ patients treated with azithromycin 500 mg daily for MAC, 3 (14%) developed hearing loss that developed 4-12 weeks after initiation of azithromycin.…”

Section: Clinical Studiesmentioning

confidence: 99%

“…However, the authors did not stipulate whether the hearing loss was temporary or permanent. Nevertheless, it would be prudent to perform audiologic monitoring in patients receiving clarithromycin, particularly if they are receiving long-term treatment (57) even though hearing impairment may be less severe and occur less frequently with high-dose clarithromycin compared to high dose azithromycin (44,53).…”

Section: Clinical Studiesmentioning

confidence: 99%

“…However, these authors did not include children under the age of 15 nor did they study patients >60 years of age. Macrolide ototoxicity has been observed in children (57,71) and published case reports suggest that the elderly and patients with HIV disease may be at higher risk of ototoxic reactions to all the commonly prescribed macrolide antibiotics, including azithromycin, clarithromycin, and erythromycin (44).…”

Section: Macrolides Clinical Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Ototoxicity of Non-aminoglycoside Antibiotics

2021

View full text Add to dashboard Cite

It is well-known that aminoglycoside antibiotics can cause significant hearing loss and vestibular deficits that have been described in animal studies and in clinical reports. The purpose of this review is to summarize relevant preclinical and clinical publications that discuss the ototoxicity of non-aminoglycoside antibiotics. The major classes of antibiotics other than aminoglycosides that have been associated with hearing loss in animal studies and in patients are discussed in this report. These antibiotics include: capreomycin, a polypeptide antibiotic that has been used to treat patients with drug-resistant tuberculosis, particularly in developing nations; the macrolides, including erythromycin, azithromycin and clarithromycin; and vancomycin. These antibiotics have been associated with ototoxicity, particularly in neonates. It is critical to be aware of the ototoxic potential of these antibiotics since so much attention has been given to the ototoxicity of aminoglycoside antibiotics in the literature.

show abstract

Section: Clinical Studiesmentioning

confidence: 99%

Section: Clinical Studiesmentioning

confidence: 99%

Section: Macrolides Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Ototoxicity of Non-aminoglycoside Antibiotics

2021

View full text Add to dashboard Cite

show abstract

Macrolide‐associated sensorineural hearing loss: A systematic review

et al. 2017

View full text Add to dashboard Cite

Objectives: To investigate the potential association of macrolide antibiotics with sensorineural hearing loss (SNHL) and which agents and dosage may be related. To evaluate whether an optimal treatment exists for reversing SNHL that occurs after macrolide therapy.Study Design: Systematic review of the literature. Methods: Computerized (PubMed, EMBASE, Cochrane Library) and manual searches were performed to identify human studies of all ages (patients) who received macrolides (intervention, with or without control) and documented SNHL (outcome). All study designs were assessed. Extracted data included macrolide regimen details, as well as the timing, severity, and reversibility of SNHL with drug cessation alone or with additional medical intervention. Study designs and the associated risk of bias were assessed.Results: The 44 publications (3 prospective, 41 retrospective) that met these criteria described 78 cases of audiometrically confirmed SNHL. SNHL was associated with oral and intravenous macrolide administration at standard and elevated doses. SNHL was irreversible in six cases, despite macrolide cessation (n 5 5) and oral steroid treatment (n 5 1). Irreversible SNHL was observed following 2 to 3 days of exposure. SNHL was reversible with macrolide cessation alone in 70 cases. In two cases, macrolide cessation coupled with oral steroid administration restored hearing. Reversible cases improved within hours to days. Nine studies also described 42 cases of subjective patient-reported hearing loss. Limitations in the data arose from study design, related comorbidities, and concomitant drug administration.Conclusion: SNHL may follow macrolide exposure, even at standard oral doses. Further research is needed to understand the incidence, prevalence, and biological mechanism of its ototoxicity.

show abstract

Azithromycin

2006

Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions

View full text Add to dashboard Cite

Azithromycin-induced hearing loss

Cited by 18 publications

References 0 publications

Ototoxicity of Non-aminoglycoside Antibiotics

Ototoxicity of Non-aminoglycoside Antibiotics

Macrolide‐associated sensorineural hearing loss: A systematic review

Azithromycin

Contact Info

Product

Resources

About